Latest Breaking News On - Cyril konto - Page 4 : comparemela.com

ICHNOS SCIENCES ENTERS LICENSING AGREEMENT FOR OX40 ANTAGONIST MONOCLONAL ANTIBODY PORTFOLIO WITH ASTRIA THERAPEUTICS

ICHNOS SCIENCES ENTERS LICENSING AGREEMENT FOR OX40 ANTAGONIST MONOCLONAL ANTIBODY PORTFOLIO WITH ASTRIA THERAPEUTICS
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

New yorkUnited statesJill milneCyril kontoPrnewswire ichnos sciencesIchnos sciences incIchnos sciencesAstria therapeuticsAstria therapeutic

ICHNOS SCIENCES ENTERS LICENSING AGREEMENT FOR OX40 ANTAGONIST MONOCLONAL ANTIBODY PORTFOLIO WITH ASTRIA THERAPEUTICS

ICHNOS SCIENCES ENTERS LICENSING AGREEMENT FOR OX40 ANTAGONIST MONOCLONAL ANTIBODY PORTFOLIO WITH ASTRIA THERAPEUTICS
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

New yorkUnited statesJill milneCyril kontoPrnewswire ichnos sciencesIchnos sciencesIchnos sciences incAstria therapeuticsAstria therapeutic

ICHNOS SCIENCES PROMOTES DEAN THOMAS TO GENERAL COUNSEL

/PRNewswire/ Ichnos Sciences Inc., a global clinical-stage biotechnology company developing innovative multispecific antibodies for oncology, today.

New yorkUnited statesCity ofUnited kingdomCyril kontoDean thomasPrnewswire ichnos sciences incIchnos sciencesUniversity of oxfordKing college londonNational attorneyIchnos sciences incSciences incGeneral counselIchno associate general counselGlobal head

ICHNOS SCIENCES RECEIVES ORPHAN DRUG DESIGNATION FOR FIRST-IN-CLASS TRISPECIFIC ANTIBODY, ISB 2001

ICHNOS SCIENCES RECEIVES ORPHAN DRUG DESIGNATION FOR FIRST-IN-CLASS TRISPECIFIC ANTIBODY, ISB 2001
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesNew yorkCyril kontoLida pacaudAshok marIchnos sciences incDrug administrationHuman research ethics committeeNational cancer instituteAmerican association for cancer researchIchnos sciencesPrnewswire ichnos sciences incSciences incChief executive officerChief medical officerAmerican association

ICHNOS SCIENCES WELCOMES LIDA PACAUD, M D , AS NEW CHIEF MEDICAL OFFICER

NEW YORK, June 26, 2023 /PRNewswire/ Ichnos Sciences Inc., a global clinical-stage biotechnology company developing innovative multispecific an.

New yorkUnited statesGeorgia generalFrance generalCyril kontoLida pacaudAshok marOncology clinical development at novartisPrnewswire ichnos sciences incAffairs at legend biotechIchnos sciences incIchnos sciencesTbilisi state medical universityHead of clinical developmentSciences incChief medical officer